Gene therapy trials to rejuvenate human cells begin

In a historic leap for anti-aging research, Life Biosciences has initiated its first human clinical trial for ER-100, an experimental gene therapy designed to rejuvenate aged cells by activating specific genes. Announced on June 9, 2026, the Boston-based biotechnology firm's Phase 1 trial targets optic neuropathies, including glaucoma and NAION, marking the first time partial epigenetic reprogramming has entered human testing to regenerate damaged optic nerve neurons and potentially reverse age-related vision loss. This pioneering effort aims to reset cells' biological clock, rather than merely treating symptoms, opening a new frontier in regenerative medicine. The stakes are extraordinarily high in this endeavor, led by Harvard geneticist and Life Biosciences co-founder David Sinclair, who posits that aging is driven by a loss of epigenetic information, which this therapy seeks to restore. The U.S. FDA, which granted Investigational New Drug clearance on January 15, 2026, is cautiously embracing rejuvenation technologies, provided they are tethered to specific, recognized diseases with measurable outcomes rather than aging as a standalone condition. Critics, however, warn of the 'high-risk' nature of reprogramming, citing concerns about potential runaway cellular growth, akin to prior cancer risks observed in preclinical models. Yet, Life Biosciences has built in crucial safety mechanisms, including intravitreal delivery to the isolated eye and a doxycycline-activated 'on-off' switch for the therapeutic genes. Looking ahead, the Phase 1 trial will primarily evaluate the safety and tolerability of ER-100, with initial data expected in Q4 2026, alongside assessments of visual function endpoints. Success here could catalyze broader applications, as Life Biosciences is already exploring its epigenetic restoration platform for other age-related conditions, including metabolic liver disease, with preclinical studies showing promise. This trial is not just about restoring sight; it's a critical test of whether the fundamental processes of aging can truly be reversed at a cellular level, potentially redefining the landscape of chronic disease treatment.